Oncolytic adenovirus gene therapy - Multivir

Drug Profile

Oncolytic adenovirus gene therapy - Multivir

Alternative Names: Ad-VirRx 007; Ad-VirRx 007 -MultiVir; Ad5-VirRx 007

Latest Information Update: 18 Apr 2016

Price : $50

At a glance

  • Originator MultiVir
  • Class Antineoplastics; Gene therapies; Oncolytic viruses
  • Mechanism of Action Apoptosis regulatory protein stimulants; Gene transference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase I Solid tumours

Most Recent Events

  • 18 Apr 2016 Phase-I clinical trials in Solid tumours in USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top